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Abstract
Background: The aim was to compare the effect of etanercept (ETN) and conventional synthetic disease-modifying
anti-rheumatic drug (DMARD) therapy on serum amyloid A (SAA) levels and to determine whether SAA reflects
rheumatoid arthritis (RA) disease activity better than C-reactive protein (CRP).
Methods: We measured SAA and CRP at baseline, 24, 48, and 102 week follow-up visits in 594 patients
participating in the Treatment of early RA (TEAR) study. We used Spearman correlation coefficients (rho) to evaluate
the relationship between SAA and CRP and mixed effects models to determine whether ETN and methotrexate
(MTX) treatment compared to triple DMARD therapy differentially lowered SAA. Akaike information criteria (AIC)
were used to determine model fits.
Results: SAA levels were only moderately correlated with CRP levels (rho = 0.58, p < 0.0001). There were significant
differences in SAA by both visit (p = 0.0197) and treatment arm (p = 0.0130). RA patients treated with ETN plus MTX
had a larger reduction in SAA than patients treated with traditional DMARD therapy. Similar results were found for
serum CRP by visit (p = 0.0254) and by treatment (p < 0.0001), with a more pronounced difference than for SAA.
Across all patients and time points, models of the disease activity score of 28 joints (DAS28)-erythrocyte
sedimentation rate (ESR) using SAA levels were better than models using CRP; the ΔAIC between the SAA and CRP
models was 305.
Conclusions: SAA may be a better biomarker of RA disease activity than CRP, especially during treatment with
tumor necrosis factor (TNF) antagonists. This warrants additional studies in other cohorts of patients on treatment
for RA.
Trial registration: (ClinicalTrials.gov identifier: NCT00259610, Date of registration: 28 November 2005)
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Background
Serum levels of systemic acute-phase reactants (APR)
such as C-reactive protein (CRP), and serum amyloid A
(SAA) are increased during active synovitis, and APR are
known to be significantly associated with joint damage
and disability on long-term follow up [1–4]. Therefore,
measurement of serum APR is commonly used as an in-
dicator of disease severity, progression and prognosis in
rheumatoid arthritis (RA).
The widely used disease activity score of 28 joints
(DAS28) is based on a count of 28 swollen and tender
joints, a measure of general health or global disease and
an inflammatory marker. The DAS28 based on erythro-
cyte sedimentation rate (DAS28-ESR) has been extensively
validated for use in clinical trials in combination with the
European League Against Rheumatism (EULAR) response
criteria [5, 6]. However, CRP and SAA have many advan-
tages over ESR, which is heavily influenced by age and sex
and has a slow response to change [7, 8]. Therefore, an al-
ternative formulation of the DAS28 based on CRP
(DAS28-CRP) was developed and validated against radio-
graphic progression and physical function [9]. However,
there is a considerable variation in CRP levels in patients
with RA, and a substantial proportion of patients with RA
have a clinically insignificant range of values [10–13]. It
has been recognized that DAS28-CRP tends to yield lower
values of disease activity than the DAS28-ESR, result-
ing in substantial classification differences [9, 14, 15]. In
addition, as DAS28 based on ESR or CRP integrates vari-
ous aspects of the disease into a single numerical value,
there can be a great discrepancy between patient and pro-
vider assessments of disease activity. RA disease activity
cannot be measured accurately by a single appropriate dis-
ease activity measure and the ideal targets of therapy re-
main elusive.
In contrast to ESR or CRP, less is known about the ac-
tions of SAA protein and the clinical usefulness of SAA
in RA. SAA is an acute-phase protein linked to the
pathogenesis of various diseases, such as atherosclerosis,
diabetes, Alzheimer's disease, and RA [16]. Clinical stud-
ies have shown that SAA could be a better predictor of
clinical outcomes than CRP in non-ST elevated acute
coronary syndromes or end-stage renal disease and a
better early predictor of severity in acute pancreatitis
[17–19]. SAA was originally of interest to investigators
studying amyloidosis, because chronic elevation of SAA
in patients with RA could lead to amyloid deposition,
resulting in systemic amyloidosis with major organ dam-
age [20]. Growing evidence suggests that acute-phase
SAA is sensitive to change, reaches much higher levels
than CRP, declines rapidly, and may therefore accurately
reflect disease activity [17, 19, 21]. In relation to diagno-
sis, disease activity, and assessment of treatment re-
sponse in RA, SAA has been shown correlate well with
disease activity, and decreases in serum SAA can be use-
ful in predicting clinical response [22–25]. However,
there is a lack of clinical studies in large groups of pa-
tients with RA to assess the value of SAA in monitoring
disease activity and predicting treatment response with
various treatments, such as traditional disease-modifying
anti-rheumatic drug (DMARD) combination therapy or
biologic therapy. It remains unclear how well SAA and
CRP correlate with disease activity during treatment and
whether SAA is better or the same as a biomarker of
disease activity during therapy.
The aim of this study was to investigate whether pa-
tients with RA treated with the TNF antagonist etaner-
cept (ETN) have greater reductions in SAA than
patients with RA treated with traditional oral DMARDs,
when both treatments result in nearly equivalent reduc-
tions in disease activity [26]. We also explored whether
SAA models RA disease activity better than CRP, espe-
cially during treatment with a TNF antagonist. There-
fore, we compared changes in SAA levels with CRP
levels in relation to disease activity measured by DAS28-
ESR and treatment modalities using data from the Treat-
ment of early RA (TEAR) study.
Methods
Patients
All study serum samples were obtained from subjects
enrolled in the TEAR study, a randomized, double-
blinded comparative effectiveness trial [26]. The TEAR
study enrolled subjects older than 18 years who was di-
agnosed with RA according to the 1987 American Col-
lege of Rheumatology (ACR) criteria [27, 28]. They also
had active disease (at least 4 swollen joints and 4 tender
joints, using a 28-joint count); positivity for rheumatoid
factor (RF) or anti-cyclic citrullinated peptide (anti-CCP)
antibodies, or if seronegative, the presence of ≥2 ero-
sions on radiographs of the hands/wrists/feet [26]. The
main objective of the TEAR trial was to determine
whether immediate and aggressive combination drug ther-
apy was more effective in controlling early RA disease ac-
tivity and underlying symptoms than methotrexate (MTX)
monotherapy and subsequent step-up treatment.
The TEAR trial was also performed to evaluate the
comparative effectiveness of two combination drug
therapies. It was designed so that patients with early RA
(defined as patients with disease duration <3 years and
<2 months of prior DMARD therapy), active (at least 4
swollen joints and 4 tender joints using a 28-joint count)
were randomized to receive MTX monotherapy, com-
bination ETN and MTX therapy (ETN/MTX), or com-
bination MTX/hydroxychloroquine (HCQ)/sulfasalazine
(SSZ) triple oral therapy. Subjects assigned to the MTX
monotherapy arm with sustained RA disease activity
(designated as having a DAS28-ESR >3.2 after 6 months
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of treatment) were randomly assigned to step up therapy
and received either combination ETN/MTX or triple oral
therapy. All centers participating in the TEAR trial re-
ceived local Institutional Review Board or Western Insti-
tutional Review Board approval and informed consent was
obtained from all study participants [26]. The members of
the TEAR study group are shown in Acknowledgements.
Serum SAA and CRP measurements
The TEAR serum samples and clinical data including
demographic information, body mass index (BMI) mea-
sured in kg/m2, rheumatoid factor (RF) positivity, prior
DMARD use, glucocorticoid use, and formal counts of
swollen and tender joints in 28 joints used in this study
were obtained when treatment was initiated and at fol-
low up visits at weeks 24, 48, and 102. CRP at baseline
was available in 594 subjects and SAA at baseline were
available in 559 subjects. There were 546 subjects with
both CRP and SAA measurements at baseline. CRP
(mg/L) was measured in plasma samples at the Clinical
and Epidemiological Research Laboratory at the Chil-
dren’s Hospital in Boston using a high-sensitivity immu-
noturbidimetric assay on a Hitachi 917 autoanalyzer
(Roche Diagnostics, Indianapolis, IN, USA), with re-
agents and calibrators from Denka Seiken (Tokyo, Japan)
[29] as previously reported [30]. High CRP was defined
as >3 mg/L [29]. We measured plasma rather than
serum CRP because of the availability of plasma speci-
mens in our study population and because the measure-
ment of CRP in plasma and serum are comparable [31].
SAA (mg/L) was measured in serum samples at Clinical
Biochemistry Research at the University of Vermont
using the Seimens BNII nephelometer (Siemens Health-
care Diagnostics, Deerfield, IL, USA). The lowest detec-
tion limit for SAA was 0.97 mg/L, determined by the
lower limit of the reference curve [32].
Statistical analysis
Summary statistics are presented as means and standard
deviations for continuous variables, and percentages for
discrete variables. Analysis of variance (ANOVA) one-
way classification was used to compare continuous base-
line clinical and demographic measures in the treatment
groups. The chi-square test was used to compare discrete
characteristics in the treatment groups.
Spearman correlation coefficients (rho) were first cal-
culated to determine the overall correlation between
SAA and CRP. To best model the relationship of SAA
and CRP, the Spearman coefficients were measured first
looking at each individual study time point while includ-
ing all study participants regardless of treatment, and
then additionally determining the relationship at each
study time point while grouping the participants by
treatment arm.
To better understand the possible treatment effects on
SAA levels over time, a repeated-measures, mixed-
effects model was used to determine whether ETN/
MTX combination therapy differentially lowered SAA
from the follow up at week 24 to the follow up at
week102. SAA level was the outcome variable of the
mixed model with the fixed effects considered being
treatment (ETN/MTX, triple oral therapy, and step-up
MTX monotherapy), the study time point (weeks 24, 48,
and 102), baseline ranked SAA value, DAS28-ESR to
control for disease activity, and the differential effect of
treatment and time that included each possible treat-
ment arm and each possible study time point. To ad-
dress the possible treatment effects on CRP over time,
another repeated-measures, mixed-effects model was
used to determine whether ETN/MTX combination
therapy differentially lowered CRP from follow up at
week 24 to follow up at week 102. CRP level was the
outcome variable for the second mixed model, with the
fixed effects considered being treatment (ETN/MTX,
triple oral therapy, and step-up MTX monotherapy), the
study time point (weeks 24, 48, and 102), baseline rank
CRP value, DAS28-ESR to control for disease activity,
and the differential effect of treatment and time interac-
tions that included each possible treatment arm and
each possible study time point.
Last, to address the second objective of the study and
to better understand whether SAA levels might model
RA disease activity (as measured by the DAS28-ESR)
better than the more traditionally used CRP, additional
repeated-measures, mixed-effects models were con-
ducted to determine the fit between (1) SAA and the
DAS28-ESR, and (2) CRP and the DAS28-ESR for pa-
tients being treated with ETN/MTX combination ther-
apy versus patients being treated with oral DMARDs.
DAS28-ESR score was the outcome variable for these
additional mixed models, with the fixed effects including
treatment and baseline rank SAA and baseline rank CRP
values, respectively. Two commonly used model selec-
tion criteria, Akaike information criteria (AIC) and
Bayesian information criteria (BIC) were used to deter-
mine the model fit. The best model in the group com-
pared is the one that minimizes these scores, in both
cases.
Results
A total of 755 subjects with RA enrolled in the TEAR
study were analyzed when treatment was initiated and at
follow-up visits at 24, 48 and 102 weeks. Subjects were
randomized to one of four treatment arms: immediate
treatment with MTX plus ETN (n = 244), immediate oral
triple therapy (MTX plus SSZ plus HCQ) (n = 132), or
step up from MTX monotherapy (n = 379) to one of the
combination therapies (either MTX plus ETN (n = 205)
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or MTX plus SSZ plus HCQ (n = 93)) at week 24 (begin-
ning of the step-up period) if the DAS28-ESR was ≥3.2.
Overall results from the TEAR trial showed that after 2
years of treatment there were equal reductions in RA
disease activity as measured by the DAS28-ESR in all
treatment arms of the study, although subjects in the
two immediate combination treatment groups demon-
strated a greater reduction in the DAS28-ESR compared
with those in the two step-up groups at week 24. This
study was performed in subjects who consented to
participation in the biorepository (n = 594), which was
similar to the overall group of TEAR participants
(data not shown).
There were no baseline differences in age, SAA, CRP,
RF status, or disease duration between the different
treatment arms of the TEAR trial (Table 1). Of the pa-
tients included, 72 % were female, and the mean disease
duration was 3.6 years (SD 6.5). Subjects had moderate
to severe disease activity (DAS28-ESR 5.8 ± 1.1) at the
time of enrollment. At the baseline visit, SAA and CRP
were 14.1 (±23.1) and 22.4 (±72.8), respectively. At the
initial visit, ESR was better correlated with CRP (rho =
0.54) than with SAA (rho = 0.29), and SAA was moder-
ately correlated with CRP (rho = 0.58) at the initial visit.
At follow-up visits, the distributions of circulating levels
of CRP and SAA were markedly skewed to the right and
the majority of subjects (n = 350 (65.1 %)) had low values
of both (CRP <10 mg/L, SAA <20 mg/L). There were 49
subjects (9.0 %) with high values of both (CRP >20 mg/L,
SAA >40 mg/L); 50 subjects (9.2 %) had high CRP
(>20 mg/L) and low SAA (<20 mg/L) but only 12
subjects (2.2 %) had high SAA with low CRP (Table 2
and Fig. 1). The correlation between SAA and CRP
was similar regardless of treatment or study visit (rho
range 0.35–0.62).
Overall, there were significant differences in SAA by
both visit (p = 0.0197) and treatment arm (p = 0.0130).
Patients with RA treated with ETN/MTX had a greater
reduction in SAA than patients treated with oral
DMARD combination therapy even after correcting for
disease activity. SAA was lower by an average of 66
ranks following treatment with ETN/MTX compared to
triple oral therapy, using the mixed-effects model. The
results were similar for serum CRP both by visit (p =
0.0254) and by treatment arm (p < 0.0001) (Fig. 2).
Serum CRP was also lower following treatment with
ETN/MTX versus triple oral therapy. With an even
more pronounced mean difference than SAA, serum
CRP was lower by an average of 144 ranks following
treatment with ETN/MTX compared to triple oral ther-
apy (Fig. 2).
Across all patients and time points, models of the
DAS28-ESR using SAA were better than models using
CRP (Table 3); lower values of the AIC and BIC indi-
cated a better model fit. In particular, AIC takes into ac-
count the goodness of fit and the number of parameters
required to achieve this. The AIC is based on the likeli-
hood function and provides the goodness of fit for the
model. In Table 3, comparing the AIC values for the
overall model ESR versus SAA (AIC = 6854) with ESR
versus CRP (AIC = 7159.3) indicates that the former
model provides the better fit (the ΔAIC between the
models was 305). The model of DAS28-ESR using SAA
was associated with an approximately sixfold better fit
versus the CRP model for patients treated with ETN/
MTX, and an approximately fivefold better fit versus the
Table 1 Baseline demographic and clinical characteristics by treatment group
Overall Treatment group P value
Immediate combination therapy Step up from MTX monotherapy
AE AT MTX (SE) SE MTX (ST) ST
Age, mean ± SD, years 49.3 ± 12.7 50.5 ± 13.4 49 ± 12.7 47.7 ± 11.9 48.9 ± 12.9 47.6 ± 12.8 48.7 ± 11.1 0.69
Female sex, n (% of total) 404 (72.3) 142 (73.6) 72 (75.8) 23 (67.6) 101 (69.7) 14 (58.3) 52 (76.5) 0.47
BMI, mean ± SD, kg/m2 30.1 ± 7.5 29.7 ± 7.2 30.4 ± 8.7 29.3 ± 5.4 30.9 ± 7.1 30 ± 5.9 29.7 ± 8.4 0.73
Disease duration,
mean ± SD, years
3.5 ± 6.4 3.4 ± 6.2 3.9 ± 7.1 2.8 ± 5.8 3 ± 5.4 4.5 ± 7.3 4.6 ± 7.5 0.47
RF-positive, n (% of total) 495 (88.6) 168 (87.1) 88 (92.6) 31 (91.2) 130 (89.7) 20 (83.3) 58 (85.3) 0.59
DAS28-ESR, mean ± SD 5.8 ± 1.1 5.8 ± 1.1 5.7 ± 1.1 5.5 ± 1.0 5.9 ± 1.1 5.6 ± 0.9 6 ± 1.1 0.20
Baseline SAA, n
(mean ± SD), mg/L
559 (22.4 ± 72.8) 193 (34.1 ± 116.6) 95 (17.4 ± 33.8) 34 (13 ± 14.4) 145 (16.1 ± 24.7) 24 (12.3 ± 38) 68 (17.9 ± 31.3) 0.16
Baseline CRP, n
(mean± SD), mg/L
594 (14.1 ± 23.1) 194 (16 ± 25.4) 104 (14.3 ± 26.1) 36 (9.7 ± 12.1) 159 (12.9 ± 20.5) 25 (8 ± 9) 76 (15.9 ± 24.8) 0.38
Among participants in the combination arm: AE immediate treatment with methotrexate (MTX) + etanercept (ETN), AT immediate oral triple disease-modifying
anti-rheumatic drug (DMARD) therapy (MTX + sulfasalazine + hydroxychloroquine). Among participants in the MTX monotherapy arm: MTX (SE) MTX only without
step-up to MTX + ETN at week 24 SE): step-up to MTX + ETN at week 24; MTX (ST) MTX only without step-up to triple DMARD therapy at week 24; ST step-up to
triple DMARD therapy at week 24. BMI body mass index, SAA serum amyloid A, RF rheumatoid factor, DAS28-ESR disease activity score in 28 joints-erythrocyte
sedimentation rate, CRP C-reactive protein
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CRP model for patients treated with oral DMARDs
(ΔAIC = 159 versus ΔAIC = 137, respectively).
Discussion
For patients with RA in the TEAR trial, both CRP and SAA
serum levels decreased over time with treatment, particu-
larly in the MTX/ETN group. Patients with RA treated
with ETN/MTX had a greater reduction in SAA than pa-
tients treated with oral DMARD therapy, even after cor-
recting for disease activity. Our findings are consistent with
previous studies that showed greater reduction in SAA with
different combination therapies such as golimumab (goli-
mumab +MTX vs MTX alone) or tofacitinb (tofacitinib +
MTX vs tofacitinib monotherapy) [22, 33]. In an observa-
tional study of 50 consecutive patients with RA treated with
long-term leflunomide, the reduction in SAA was transient,
as it was no longer observed after 6 months, in spite of re-
duced disease activity [23]. In our study, the ETN/MTX
treatment group had a sustained reduction in SAA by week
102, although the difference was not statistically significant.
Our study also compared SAA with CRP to study the
usefulness of SAA for detecting systemic inflammation
and for monitoring various treatments including anti-
TNF treatment in early RA. The advantages of SAA as a
biomarker of disease activity in early RA include the
rapid production and exceptionally wide dynamic range
of the SAA response [34, 35]. During acute inflamma-
tion, serum SAA may rise up to 1000-fold and the bio-
logic half-life of SAA is significantly shorter than that of
CRP [36, 37]. Connolly et al. showed that baseline SAA,
but not ESR or CRP, correlates with the 28-joint swollen
joint count and is independently associated with radio-
graphic evidence of progression at 1 year [38]. In
addition, SAA has a direct role in synovial inflammation
and joint destruction [16, 38–42]. We demonstrated in-
creased expression of SAA in patients with early active
RA and observed moderate significant correlations be-
tween SAA and CRP regardless of treatment or study
visit. In addition, SAA might model RA disease activity
(as measured by the DAS28-ESR) better than CRP [34].
Table 2 Distribution of serum serum amyloid A (SAA) and
C-reactive protein (CRP) at the baseline study visit
CRP (mg/L) SAA(mg/L)
<20 20-40 >40 Total
<10 Frequency (n) 350 26 12 390
Row (%) 89.7 7.2 3.1 100
Column (%) 83.5 43.1 19.4 71.4
10-20 Frequency (n) 19 12 1 32
Row (%) 59.4 37.5 3.1 100
Column (%) 4.5 18.5 1.6 5.9
>20 Frequency (n) 50 25 49 124
Row (%) 40.3 20.2 39.5 100
Column (%) 11.9 38.5 79.0 22.7
Total Frequency (n) 419 65 62 546
Row (%) 76.7 11.9 11.4 100
Column (%) 100 100 100 100
Fig. 1 Serum amyloid A (SAA) (mg/L) and C-reactive protein (CRP) (mg/L) at the baseline study visit
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Therefore, elevated serum SAA can be a useful marker
of disease activity and may be a more accurate indicator
of clinical outcome in early RA [38].
Interestingly, the differential effect on SAA of ETN/MTX
compared to triple oral DMARDs was less pronounced
than the differential effects on CRP of ETN/MTX
compared to triple oral DMARDs. The acute phase reac-
tion is an integrated response involving a number of cyto-
kines, hormones, steroids, and prostaglandins. SAA and
CRP are synthesized under the influence of different cyto-
kine combinations, and their function and contribution to
the acute phase response may be very different [43, 44].
CRP is predominantly stimulated by interleukin-6, while
SAA responds preferentially to interleukin-1 [39, 45]. Al-
though CRP has been used widely to monitor disease activ-
ity in RA, TNF antagonist therapy (and likely therapy with
other biologic agents) can reduce CRP, even without an as-
sociated reduction in RA disease activity. Our results sug-
gest that SAA might model RA disease activity better and
may be less affected by specific treatments with different
mechanisms of action.
Our study has many limitations. Subjects in our study
were limited to those with early active RA, which may
limit the generalizability of our findings, especially in pa-
tients with long disease duration. There is no gold stand-
ard to measure RA disease activity objectively.
Therefore, using DAS28-ESR as a gold standard to com-
pare biomarkers has its own limitation. ESR is influ-
enced by other factors not related to RA disease activity.
The DAS28-ESR and DAS28-CRP definitions differ sub-
stantially in classifying patients with RA, with the ESR
definition resulting in a higher proportion of patients
with high DAS-28 especially among women [46]. In
addition, the role of SAA in the pathogenesis of RA was
based on a number of studies with recombinant SAA
(rSAA). Although rSAA is a potent pro-inflammatory
mediator, the present findings show that this activity is
not shared by endogenous SAA [47, 48]. SAA is known
to be less influenced by age and gender, but is deter-
mined by many other conditions such as metabolic syn-
drome, diabetes, dietary intake, etc., and the regulatory
mechanism of SAA is not well-understood [49–52]. In
our study SAA levels varied widely across patients and
time points. Although there were statistically significant
differences in SAA by both visit and treatment arm,
Table 3 Determining model fit for rheumatoid arthritis disease activity (as measured by the DAS28-ESR) by serum SAA and CRP
AIC fit statistic ΔAIC BIC fit statistic Parameter estimate (SE) P value
Overall
DAS28-ESR vs. SAA 6854.0 305 6876.1 0.006(0.001) <.0001
DAS28-ESR vs. CRP 7159.3 7181.5 0.038(0.002) <.0001
By treatment – ETN
DAS28-ESR vs. SAA 4068.2 159 4087.7 0.007(0.001) <.0001
DAS28-ESR vs. CRP 4227.2 4246.8 0.041(0.003) <.0001
By treatment – DMARD
DAS28-ESR vs. SAA 2737.6 137 2762.2 0.006(0.002) 0.0007
DAS28-ESR vs. CRP 2875.0 2899.7 0.029(0.003) <.0001
AIC Akaike information criterion, BIC Bayesian information criterion, SE standard error, DAS28 disease activity score in 28 joints, ESR erythrocyte sedimentation rate,
SAA serum amyloid A, CRP C-reactive protein, ETN etanercept, DMARD disease-modifying anti-rheumatic drug
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Fig. 2 Mean serum amyloid A (SAA) (a) and C-reactive protein (CRP)
(b) by treatment modality and study visit. MTX methotrexate, ETN
etanercept, DMARD disease-modifying anti-rheumatic drug. Error bar
denotes standard deviation
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differences in the ranks of SAA identified by nonpara-
metric statistical tests may not be useful in daily prac-
tice, given the wide variation and right-skewed
distribution. There were marked overlaps of the distribu-
tions of absolute values, which raises concern about the
practical usefulness of SAA as a single biomarker for
disease activity measurement (Fig. 2).
Conclusions
With all limitations considered, the lack of strong correl-
ation between SAA and CRP levels, less pronounced dif-
ferential effects using biologic DMARDs and traditional
DMARDs, coupled with their superior modeling of RA
disease activity, suggests that SAA may be a better bio-
marker for RA disease activity than CRP, especially dur-
ing treatment with TNF antagonists.
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